Michael Gorin, M.D., Ph.D. (UCLA) - Ophthalmologist; medical retina and ophthalmic genetics, with specialty in retinal degeneration. Will likely lead our Phase I clinical trial.

Andrew Smith, Ph.D. (USC) - Computational biologist with expertise in gene regulation; maps out transcription factors involved in gene expression.

Elliott Sohn, M.D. (USC) - Opthalmologist and retinal surgeon; trained at Moorfields Eye Hospital and Doheny Eye Institute.

Andrew Taylor, Ph.D. (Harvard) - Professor of ophthalmology; ocular immunology, immunosuppression, and immunoregulation of the eye.